Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — Currency translation
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Affordable Medicines | Specialty | Av KARE | Total |
|---|---|---|---|---|
| Balance as of December 31, 2024 | $161,659 | $366,312 | $69,465 | $597,436 |
| Currency translation | (1,966) | — | — | (1,966) |
| Balance as of December 31, 2025 | 159,693 | 366,312 | 69,465 | 595,470 |
| Currency translation | (1,971) | — | — | (1,971) |
| Balance as of June 30, 2026 | $157,722 | $366,312 | $69,465 | $593,499 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — currency translation?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — currency translation of $0 in Q2 2026.
- What does avkare — currency translation mean?
- Captures the gains or losses resulting from converting the financial results of the AvKARE segment from its functional currency into the reporting currency of the parent company. This metric highlights the impact of foreign exchange rate fluctuations on the segment's reported financial performance.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — currency translation.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude